AR020934A1 - Compuestos trombopoyeticos - Google Patents

Compuestos trombopoyeticos

Info

Publication number
AR020934A1
AR020934A1 ARP990105333A AR020934A1 AR 020934 A1 AR020934 A1 AR 020934A1 AR P990105333 A ARP990105333 A AR P990105333A AR 020934 A1 AR020934 A1 AR 020934A1
Authority
AR
Argentina
Prior art keywords
compounds
thrombopoyetic
polypeptides
peptides
platelet
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Chuan-Fa Lui
Ulrich Feige
Janet Cheetam
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Publication of AR020934A1 publication Critical patent/AR020934A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP990105333 1998-10-23 1999-10-22 Compuestos trombopoyeticos AR020934A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10534898P 1998-10-23 1998-10-23

Publications (1)

Publication Number Publication Date
AR020934A1 true AR020934A1 (es) 2002-06-05

Family

ID=22305310

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105333 AR020934A1 (es) 1998-10-23 1999-10-22 Compuestos trombopoyeticos

Country Status (36)

Country Link
US (8) US6835809B1 (cg-RX-API-DMAC10.html)
EP (3) EP1124961B9 (cg-RX-API-DMAC10.html)
JP (2) JP3820105B2 (cg-RX-API-DMAC10.html)
KR (1) KR100719202B1 (cg-RX-API-DMAC10.html)
CN (2) CN1250721C (cg-RX-API-DMAC10.html)
AR (1) AR020934A1 (cg-RX-API-DMAC10.html)
AT (1) ATE348163T1 (cg-RX-API-DMAC10.html)
AU (1) AU773891C (cg-RX-API-DMAC10.html)
BG (3) BG65663B1 (cg-RX-API-DMAC10.html)
BR (1) BRPI9914698B8 (cg-RX-API-DMAC10.html)
CA (1) CA2346996C (cg-RX-API-DMAC10.html)
CY (4) CY1107526T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ302155B6 (cg-RX-API-DMAC10.html)
DE (2) DE69934425T2 (cg-RX-API-DMAC10.html)
DK (3) DK1124961T3 (cg-RX-API-DMAC10.html)
EA (1) EA003998B1 (cg-RX-API-DMAC10.html)
ES (3) ES2422231T3 (cg-RX-API-DMAC10.html)
FR (1) FR09C0030I2 (cg-RX-API-DMAC10.html)
HK (1) HK1042114B (cg-RX-API-DMAC10.html)
HU (1) HU228582B1 (cg-RX-API-DMAC10.html)
IL (1) IL142023A0 (cg-RX-API-DMAC10.html)
LT (1) LTC1124961I2 (cg-RX-API-DMAC10.html)
LU (1) LU91598I2 (cg-RX-API-DMAC10.html)
ME (2) MEP42108A (cg-RX-API-DMAC10.html)
MY (1) MY126795A (cg-RX-API-DMAC10.html)
NL (1) NL300398I2 (cg-RX-API-DMAC10.html)
NO (2) NO331027B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ510529A (cg-RX-API-DMAC10.html)
PL (1) PL219605B1 (cg-RX-API-DMAC10.html)
PT (3) PT1783222E (cg-RX-API-DMAC10.html)
RS (1) RS51237B (cg-RX-API-DMAC10.html)
SI (3) SI2319928T1 (cg-RX-API-DMAC10.html)
SK (1) SK287737B6 (cg-RX-API-DMAC10.html)
TW (2) TWI250988B (cg-RX-API-DMAC10.html)
WO (1) WO2000024770A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200102102B (cg-RX-API-DMAC10.html)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
MXPA02010351A (es) * 2000-04-21 2003-04-25 Amgen Inc Antagonistas de integrina/adhesion.
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
AU2001269762C1 (en) * 2000-06-09 2005-12-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ES2316919T3 (es) 2000-12-05 2009-04-16 Alexion Pharmaceuticals, Inc. Anticuerpos diseñados racionalmente.
US20040018203A1 (en) * 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
JP4402455B2 (ja) 2001-08-17 2010-01-20 エンカム ファーマシューティカルズ アクティーゼルスカブ 細胞の分化、増殖、再生、可塑性及び生存に影響を及ぼすことができる化合物
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CA2499625A1 (en) * 2002-09-18 2004-04-01 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
MXPA05012313A (es) 2003-05-12 2006-04-18 Affymax Inc Peptidos que se unen al receptor de eritropoyetina.
CN1849141A (zh) 2003-05-12 2006-10-18 阿费麦克斯公司 用于聚(乙二醇)修饰的肽的间隔臂部分
RS51130B (sr) 2003-05-12 2010-10-31 Affymax Inc. Novi peptidi koji se vezuju za eritropoietinski receptor
DE602004028725D1 (de) * 2003-05-12 2010-09-30 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
ES2390082T5 (es) * 2004-06-30 2018-01-19 Nektar Therapeutics Conjugados de resto de Factor IX y polímeros
CA2572765C (en) * 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EA200800109A1 (ru) * 2005-06-23 2008-06-30 Аплаген Гмбх Суправалентные соединения
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007075899A2 (en) * 2005-12-21 2007-07-05 Maxygen, Inc. Dual agonist compounds and uses thereof
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
EP1986677A2 (en) * 2006-01-25 2008-11-05 Amgen Inc. Thrombopoietic compounds
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
AU2007278748B2 (en) * 2006-07-24 2013-08-15 The University Of Queensland Method of producing a population of cells
WO2008095004A2 (en) 2007-01-31 2008-08-07 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
JP5591691B2 (ja) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
EP2197421A1 (en) * 2007-08-31 2010-06-23 Amgen, Inc Solid-state protein formulation
WO2009043049A2 (en) 2007-09-27 2009-04-02 Amgen Inc. Pharmaceutical formulations
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US8470964B2 (en) 2007-11-28 2013-06-25 Enkam Pharmaceuticals A/S Peptides derived from NCAM (FGLs)
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2414391B1 (en) 2009-04-02 2018-11-28 Roche Glycart AG Multispecific antibodies comprising full length antibodies and single chain fab fragments
US20120302737A1 (en) 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US20120253009A1 (en) * 2009-10-16 2012-10-04 Amgen Inc. Thrombopoietic compounds
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
BR112012027001A2 (pt) 2010-04-23 2016-07-19 Genentech Inc produção de proteínas heteromultiméricas
PT2575935E (pt) 2010-06-07 2015-10-20 Amgen Inc Dispositivo de administração de medicamento
BR112013003279A2 (pt) 2010-08-13 2016-06-14 Genentech In “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
MX383982B (es) 2010-09-22 2025-03-14 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
BR112013019499B1 (pt) 2011-02-04 2023-01-10 Genentech, Inc. Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CA2831100C (en) 2011-03-31 2020-02-18 Mark Dominis Holt Vial adapter and system
ES2926520T3 (es) 2011-04-20 2022-10-26 Amgen Inc Aparato autoinyector
HK1202878A1 (en) 2011-10-11 2015-10-09 F. Hoffmann-La Roche Ag Improved assembly of bispecific antibodies
TR201807808T4 (tr) 2011-10-14 2018-06-21 Amgen Inc Enjektör ve montaj yöntemi.
JP6486686B2 (ja) 2012-02-10 2019-03-20 ジェネンテック， インコーポレイテッド 単鎖抗体及び他のヘテロ多量体
CN102552184A (zh) * 2012-02-16 2012-07-11 山东泉港药业有限公司 一种血小板生成素拟肽冻干制剂
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
EP3072548B1 (en) 2012-11-21 2019-03-06 Amgen, Inc Drug delivery device
TWI592183B (zh) 2013-03-15 2017-07-21 安美基公司 本體輪廓可調適之自動注射器裝置
CN104046642B (zh) * 2013-03-15 2018-07-06 兰州大学 发酵生产二聚体化融合蛋白的方法
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
EP3593839A1 (en) 2013-03-15 2020-01-15 Amgen Inc. Drug cassette
CN104045715B (zh) * 2013-03-15 2018-05-01 兰州大学 二聚体化融合蛋白的制备及应用
JP6670740B2 (ja) 2013-03-22 2020-03-25 アムジエン・インコーポレーテツド 注入器および組み立て法
US10668053B2 (en) 2013-05-03 2020-06-02 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
PL3060275T3 (pl) 2013-10-24 2019-12-31 Amgen Inc. Wstrzykiwacz i sposób montażu
AU2014340174B2 (en) 2013-10-24 2019-09-12 Amgen Inc. Drug delivery system with temperature-sensitive control
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
CN105017408B (zh) * 2014-04-30 2019-11-05 重庆派金生物科技有限公司 聚乙二醇化血小板生成素模拟肽同源四聚体及其用途
EP3140392B1 (en) 2014-05-06 2023-07-26 F. Hoffmann-La Roche AG Production of heteromultimeric proteins using mammalian cells
CA3193070A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
EP4362039A3 (en) 2014-06-03 2024-08-07 Amgen Inc. Controllable drug delivery system and method of use
JP6655011B2 (ja) * 2014-06-23 2020-02-26 東亞合成株式会社 細胞の多核化を誘導するペプチドおよびその利用
TN2017000109A1 (en) * 2014-09-26 2018-07-04 Bayer Pharma AG Stabilized adrenomedullin derivatives and use thereof
JP6766040B2 (ja) 2014-10-14 2020-10-07 アムジエン・インコーポレーテツド 視覚および可聴インジケータを備える薬剤注射装置
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
WO2016129656A1 (ja) * 2015-02-12 2016-08-18 国立大学法人岩手大学 哺乳動物細胞に対する外来遺伝子の導入効率の向上剤
WO2016133947A1 (en) 2015-02-17 2016-08-25 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EP3386573B1 (en) 2015-12-09 2019-10-02 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
ES2814287T3 (es) 2016-03-15 2021-03-26 Amgen Inc Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
US10988284B2 (en) 2016-05-13 2021-04-27 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
CN108264547B (zh) * 2016-12-30 2021-09-21 四川科伦博泰生物医药股份有限公司 一种纯化蛋白的方法以及试剂盒
CA3049780A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
CA3052204A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
AU2018231107B2 (en) 2017-03-06 2023-04-20 Amgen Inc. Drug delivery device with activation prevention feature
WO2018164829A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
IL303449B2 (en) 2017-03-09 2024-08-01 Amgen Inc Insertion mechanism for a drug delivery device
HUE072005T2 (hu) 2017-03-11 2025-10-28 Cartesian Therapeutics Inc Gyulladásgátlókkal és immunszupresszánst tartalmazó szintetikus nanohordozókkal történõ kombinált kezeléssel összefüggõ eljárások és készítmények
LT3600491T (lt) 2017-03-28 2023-10-10 Amgen Inc. Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas
US11904143B2 (en) 2017-06-08 2024-02-20 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
US11541183B2 (en) 2017-06-22 2023-01-03 Amgen Inc. Device activation impact/shock reduction
US11395880B2 (en) 2017-06-23 2022-07-26 Amgen Inc. Electronic drug delivery device
EP3651832B1 (en) 2017-07-14 2023-12-13 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
EP4085942A1 (en) 2017-07-25 2022-11-09 Amgen Inc. Drug delivery device with gear module and related method of assembly
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
US11826480B2 (en) 2017-11-03 2023-11-28 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
MX2020004736A (es) 2017-11-10 2020-08-13 Amgen Inc Embolos para dispositivos de administracion de farmacos.
SG11202002772VA (en) 2017-11-16 2020-04-29 Amgen Inc Autoinjector with stall and end point detection
EP3710090A1 (en) 2017-11-16 2020-09-23 Amgen Inc. Door latch mechanism for drug delivery device
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MX2021000749A (es) 2018-07-24 2021-03-29 Amgen Inc Dispositivos de suministro para administrar farmacos.
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
AU2019347710B2 (en) 2018-09-24 2025-05-08 Amgen Inc. Interventional dosing systems and methods
EP3856283A1 (en) 2018-09-28 2021-08-04 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
CA3112214A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
MX2021002791A (es) 2018-10-15 2021-05-12 Amgen Inc Proceso de ensamblaje de plataforma para un dispositivo de administracion de farmacos.
US12053617B2 (en) 2018-10-15 2024-08-06 Amgen Inc. Drug delivery device having damping mechanism
CN112888453A (zh) * 2018-10-26 2021-06-01 协和麒麟株式会社 用于治疗再生障碍性贫血的药物组合物
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US12485219B2 (en) 2018-11-01 2025-12-02 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
MX2021012557A (es) 2019-04-24 2021-11-12 Amgen Inc Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
WO2020223303A1 (en) 2019-04-29 2020-11-05 The Children's Hospital Of Philadelphia Compositions and methods for increasing megakaryocyte production
MX2022002149A (es) 2019-08-23 2022-03-17 Amgen Inc Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
AU2021399935A1 (en) 2020-12-18 2023-06-29 Richter Gedeon Nyrt. Methods for the purification of refolded fc-peptide fusion protein
US20240156973A1 (en) * 2021-02-24 2024-05-16 Purdue Research Foundation Osteotropic compositions and uses thereof
CN113402614A (zh) * 2021-04-22 2021-09-17 山东泉港药业有限公司 血小板生成素拟肽融合蛋白(fc-tmp)编码基因与应用
BR112023024278A2 (pt) 2021-05-21 2024-01-30 Amgen Inc Método de otimizar uma receita de enchimento para um recipiente de fármacos
WO2023044774A1 (en) * 2021-09-24 2023-03-30 Sichuan Clover Biopharmaceuticals, Inc. Tpo mimetic fusion proteins and methods of use submission of sequence listing as ascii text file
CN118973600A (zh) 2022-02-02 2024-11-15 国立大学法人筑波大学 用于脐带血移植后的血细胞恢复的药物组合物
MX2024010846A (es) 2022-03-24 2024-09-11 Richter Gedeon Nyrt Metodo para la preparacion de biofarmacos.
US20240148841A1 (en) 2022-08-11 2024-05-09 Selecta Biosciences Inc. Compositions and methods related to immunoglobulin proteases and fusions thereof
WO2025037108A2 (en) 2023-08-15 2025-02-20 Board Of Trustees Of The Leland Stanford Junior University Modified thrombopoietin
CN117986346B (zh) * 2024-04-07 2024-07-26 中国人民解放军军事科学院军事医学研究院 一种tpo模拟肽及其应用
CN119780301B (zh) * 2025-01-10 2025-08-01 山东泉港药业有限公司 一种血小板生成素拟肽的肽图检测分析方法

Family Cites Families (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3694016A (en) * 1969-09-01 1972-09-26 John Patrick Scallan Cover-lock for containers
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4503235A (en) 1983-03-11 1985-03-05 Warner-Lambert Company Process for producing 4-carbamoyl-1H-imidazolium-5-olate
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JP2876058B2 (ja) 1986-08-18 1999-03-31 エミスフィア・テクノロジーズ・インコーポレイテッド 薬物送達システム
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
ATE106249T1 (de) 1987-11-05 1994-06-15 Hybritech Inc Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
AU638964B2 (en) 1988-12-22 1993-07-15 Genentech Inc. Method for preparing water soluble polypeptides
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5216131A (en) 1989-02-23 1993-06-01 Genentech, Inc. Lymphocyte homing receptors
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992001718A2 (en) 1990-07-17 1992-02-06 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides and ligand for gmp-140
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1992016192A1 (en) 1991-03-15 1992-10-01 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6139843A (en) 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
CA2312667C (en) * 1991-10-25 2002-11-19 Immunex Corporation Novel cytokine
US5376367A (en) 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
CA2118130A1 (en) 1992-04-14 1993-10-28 Jean M. J. Frechet Dendritic based macromolecules and method of production
CA2131003A1 (en) 1992-05-26 1993-12-09 Raymond G. Goodwin Novel cytokine that binds cd30
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
DE69334287D1 (de) 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
GB9225448D0 (en) 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
NZ247231A (en) * 1993-03-23 1994-10-26 Holyoake Ind Ltd Diffuser for air conditioning system; outlet air direction thermostatically controlled
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
US5786331A (en) 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
BR9505781A (pt) * 1994-02-14 1996-03-05 Kirin Brewery Proteina tendo atividade TPO
NZ271230A (en) 1994-02-14 1998-03-25 Zymogenetics Inc Hematopoietic proteins, production and use
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
CN1229385C (zh) 1994-03-31 2005-11-30 安姆根有限公司 刺激巨核细胞生长和分化的组合物及方法
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
IL111196A0 (en) 1994-10-07 1994-12-29 Yeda Res & Dev Peptides and pharmaceutical compositions comprising them
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU693478B2 (en) 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
IL116026A (en) 1994-11-22 2005-08-31 Rhone Poulenc Rorer Sa Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses
JP3511321B2 (ja) * 1994-11-29 2004-03-29 出光興産株式会社 スチレン系重合体の分子量制御方法
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
AU700605B2 (en) 1994-12-07 1999-01-07 Bionebraska, Inc. Production of peptides using recombinant fusion protein constructs
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
US5888763A (en) 1994-12-30 1999-03-30 The Rockefeller University Peptides specific for the first Crk-SH3 domain
AU3204895A (en) 1995-02-01 1996-08-21 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
IL113159A0 (en) 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
YU34196A (sh) * 1995-06-07 1999-03-04 Glaxo Group Limited Peptidi i jedinjenja koja se vezuju za receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
KR100436680B1 (ko) 1995-06-07 2004-09-18 글락소 그룹 리미티드 트롬보포이에틴 수용체에 결합하는 펩티드 및 화합물
IL118524A (en) 1995-06-19 2004-02-19 Akzo Nobel Nv Peptides and pharmaceutical preparations containing them useful in the treatment of peptide tolerance
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US5746516A (en) 1995-08-11 1998-05-05 Hitachi Powdered Metals Co., Ltd. Porous bearing system having internal grooves and electric motor provided with the same
WO1997008553A1 (en) 1995-08-22 1997-03-06 The Regents Of The University Of California Targeting of proteins to the cell wall of gram-positive bacteria
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
JPH09151200A (ja) 1995-09-29 1997-06-10 Ajinomoto Co Inc ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤
US5670110A (en) 1995-12-21 1997-09-23 The Procter & Gamble Company Method for making three-dimensional macroscopically-expanded webs having improved functional surfaces
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
CN1154971A (zh) * 1996-01-19 1997-07-23 北京医科大学 血小板生长因子(tpo)及其制备方法和用途
US5714577A (en) 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
EP0904112B1 (en) 1996-02-09 2009-11-18 Amgen Inc., Composition comprising il-1ra as interleukin-1 inhibitor and hyaluronan as controlled release polymer
IL117223A0 (en) 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
JP4088344B2 (ja) 1996-03-28 2008-05-21 カイロン コーポレイション ウロキナーゼレセプターのペプチドリガンド
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
FR2748028B1 (fr) 1996-04-30 1998-08-14 Lab Francais Du Fractionnement Peptides derives du facteur von willebrand et leur utilisation comme anticoagulant
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1997046668A1 (en) 1996-06-07 1997-12-11 Takeda Chemical Industries, Ltd. Novel peptide, process for the production of the same, and use of the same
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
AU4412297A (en) 1996-09-10 1998-04-02 Burnham Institute, The Tumor homing molecules, conjugates derived therefrom, and methods of using sa me
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
AU736876B2 (en) 1996-12-06 2001-08-02 Amgen, Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
KR100937550B1 (ko) 1996-12-20 2010-01-19 암젠 인코포레이티드 Ｏｂ 융합 단백질 조성물과 이 단백질의 제조 방법
KR19980066046A (ko) 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
US5955431A (en) 1997-02-05 1999-09-21 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
US5863735A (en) 1997-02-24 1999-01-26 Incyte Pharmaceuticals, Inc. Human transmembrane 4 superfamily protein
NZ500253A (en) 1997-04-16 2002-09-27 Amgen Inc Osteoprotegerin binding proteins and receptors
ES2183351T3 (es) 1997-04-17 2003-03-16 Amgen Inc Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos.
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
WO1998055620A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
EP0998577B1 (en) 1997-07-24 2004-10-27 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6238667B1 (en) 1997-09-19 2001-05-29 Heinz Kohler Method of affinity cross-linking biologically active immunogenic peptides to antibodies
CA2306246A1 (en) 1997-10-06 1999-04-15 Millennium Pharmaceuticals, Inc. Signal peptide containing proteins and uses therefor
CN1138472C (zh) 1997-10-10 2004-02-18 西托维亚公司 二肽型编程性细胞死亡抑制剂及其用途
ES2173641T3 (es) 1997-11-07 2002-10-16 Conjuchem Inc Composicion de derivados opiaceos para la fabricacion de medicamentos.
WO1999038526A1 (en) 1998-01-29 1999-08-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variant peptide ligands that selectively induce apoptosis
US6162613A (en) 1998-02-18 2000-12-19 Vertex Pharmaceuticals, Inc. Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
JP2002505338A (ja) 1998-03-05 2002-02-19 カイロン コーポレイション 生物学的に活性な分子の血清半減期を増加するための方法
US6235872B1 (en) 1998-03-12 2001-05-22 The Burnham Institute Proapoptotic peptides dependence polypeptides and methods of use
JP4361684B2 (ja) 1998-03-20 2009-11-11 中外製薬株式会社 エリトロポエチン受容体のためのペプチドリガンド
EP0947524A1 (en) 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
DE69925829D1 (de) 1998-04-06 2005-07-21 Advanced Immunitt Inc Kurzes peptid zur behandlung neurodegenerativer erkrankungen
DE69925830T2 (de) 1998-04-28 2006-05-04 Applied Research Systems Ars Holding N.V. Peg-lhrh analog konjugate
EP0972780A1 (en) 1998-05-18 2000-01-19 Applied Research Systems ARS Holding N.V. Il-6 antagonist peptides
EP0958829B1 (en) 1998-05-21 2004-05-19 Tecnogen S.C.P.A. Use of a peptide compound in the treatment of systemic lupus erythematosus
AU764277B2 (en) 1998-05-22 2003-08-14 Abbvie Inc. Peptide antiangiogenic drugs
US5932548A (en) 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
WO2000001402A1 (en) 1998-07-02 2000-01-13 Envision Biomedical Consulting Antiproliferative and antiviral proteins and peptides
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6906170B1 (en) 1998-08-21 2005-06-14 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides derived from IL-2 and analogues thereof
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU2880400A (en) 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
US6635646B1 (en) 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
WO2001002440A1 (en) 1999-07-02 2001-01-11 Genentech, Inc. Fusion peptides comprising a peptide ligand domain and a multimerization domain
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001259432B2 (en) 2000-05-03 2005-04-21 Amgen Inc. Modified peptides, comprising an FC domain, as therapeutic agents
ES2316919T3 (es) 2000-12-05 2009-04-16 Alexion Pharmaceuticals, Inc. Anticuerpos diseñados racionalmente.
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
AU2002307062A1 (en) 2001-04-02 2002-10-15 Purdue Pharma L.P. Thrombopoietin (tpo) synthebody for stimulation of platelet production
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
CA2490409A1 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
JP2005536992A (ja) 2002-06-28 2005-12-08 セントカー・インコーポレーテツド 哺乳動物のｅｐｏ模倣ｃｈ１欠失ミメティボディ、組成物、方法および使用
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2004058988A2 (en) 2002-12-20 2004-07-15 Amgen, Inc. Binding agents which inhibit myostatin
CN1871022B (zh) 2003-08-28 2011-07-06 奥索-麦克尼尔药品公司 结合血小板生成素受体的肽和化合物
CA2572765C (en) 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
JP5517450B2 (ja) 2005-03-10 2014-06-11 バイオンテック アーゲー 二量体または多量体のマイクロタンパク質
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1986677A2 (en) 2006-01-25 2008-11-05 Amgen Inc. Thrombopoietic compounds
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US8197642B2 (en) * 2007-07-26 2012-06-12 Nichiha Corporation Inorganic board and method for manufacturing the same
US10534898B2 (en) 2017-01-18 2020-01-14 International Business Machines Corporation Code identification

Also Published As

Publication number Publication date
BG105401A (en) 2003-02-28
SI1124961T1 (sl) 2007-06-30
US20050080014A1 (en) 2005-04-14
CA2346996A1 (en) 2000-05-04
US20150024431A1 (en) 2015-01-22
ES2388341T3 (es) 2012-10-11
CN1810832A (zh) 2006-08-02
DK1124961T3 (da) 2007-04-10
DK1783222T3 (da) 2012-07-09
BR9914698B1 (pt) 2014-04-29
US20090186822A1 (en) 2009-07-23
NO2012005I1 (no) 2012-04-02
CN1250721C (zh) 2006-04-12
NO20011962D0 (no) 2001-04-20
TWI250988B (en) 2006-03-11
US6835809B1 (en) 2004-12-28
ES2279649T3 (es) 2007-08-16
US20120034657A1 (en) 2012-02-09
WO2000024770A9 (en) 2000-10-26
TW200606175A (en) 2006-02-16
ZA200102102B (en) 2001-11-15
NO20011962L (no) 2001-06-21
EP1124961B9 (en) 2010-07-21
NL300398I2 (nl) 2009-12-01
MEP42108A (en) 2011-02-10
SI1783222T1 (en) 2012-09-28
BG65663B1 (bg) 2009-05-29
EP1124961B1 (en) 2006-12-13
EP1783222A1 (en) 2007-05-09
LTPA2009006I1 (lt) 2022-03-10
HUP0104327A3 (en) 2003-09-29
SI2319928T1 (sl) 2013-08-30
NO2012005I2 (no) 2015-02-02
PT2319928E (pt) 2013-06-28
DE122009000039I1 (de) 2009-11-05
US20120208760A1 (en) 2012-08-16
PT1124961E (pt) 2007-02-28
LU91598I2 (fr) 2009-09-30
EP2319928B9 (en) 2014-04-16
CA2346996C (en) 2013-11-19
FR09C0030I2 (fr) 2010-12-31
PT1783222E (pt) 2012-07-26
FR09C0030I1 (fr) 2009-09-25
EP2319928B1 (en) 2013-03-27
JP3820105B2 (ja) 2006-09-13
AU773891C (en) 2005-02-17
BRPI9914698B8 (pt) 2021-05-25
HK1042114A1 (en) 2002-08-02
DK2319928T3 (da) 2013-06-24
DE69934425T2 (de) 2007-09-27
CZ20011287A3 (cs) 2001-10-17
CY2009012I2 (el) 2010-07-28
CN1810832B (zh) 2012-12-12
BG110221A (en) 2009-06-30
US8044174B2 (en) 2011-10-25
JP2002536960A (ja) 2002-11-05
ES2422231T3 (es) 2013-09-09
NO331027B1 (no) 2011-09-12
US7994117B2 (en) 2011-08-09
PL348041A1 (en) 2002-05-06
BG66190B1 (bg) 2011-12-30
CY1113107T1 (el) 2016-04-13
US20070142295A1 (en) 2007-06-21
SK4962001A3 (en) 2001-12-03
DE69934425D1 (en) 2007-01-25
US8618044B2 (en) 2013-12-31
MY126795A (en) 2006-10-31
EA003998B1 (ru) 2003-12-25
HK1042114B (zh) 2006-09-29
WO2000024770A3 (en) 2000-09-14
CY1107526T1 (el) 2010-07-28
JP2006230413A (ja) 2006-09-07
CY1114940T1 (el) 2016-12-14
EP2319928A1 (en) 2011-05-11
HU228582B1 (en) 2013-04-29
US9145450B2 (en) 2015-09-29
EP1783222B1 (en) 2012-06-06
YU24301A (sh) 2005-07-19
CN1325447A (zh) 2001-12-05
WO2000024770A2 (en) 2000-05-04
PL219605B1 (pl) 2015-06-30
RS51237B (sr) 2010-12-31
NL300398I1 (nl) 2009-10-01
US8748571B2 (en) 2014-06-10
HK1093075A1 (en) 2007-02-23
BR9914698A (pt) 2003-01-07
ATE348163T1 (de) 2007-01-15
NZ510529A (en) 2003-10-31
IL142023A0 (en) 2002-03-10
KR100719202B1 (ko) 2007-05-16
KR20010099695A (ko) 2001-11-09
US20060189531A1 (en) 2006-08-24
TWI257394B (en) 2006-07-01
CZ302155B6 (cs) 2010-11-18
HUP0104327A2 (hu) 2002-02-28
AU773891B2 (en) 2004-06-10
EA200100465A1 (ru) 2001-10-22
LU91598I9 (cg-RX-API-DMAC10.html) 2019-01-03
CY2009012I1 (el) 2010-07-28
JP4332163B2 (ja) 2009-09-16
EP1124961A2 (en) 2001-08-22
US9534032B2 (en) 2017-01-03
AU1223900A (en) 2000-05-15
LTC1124961I2 (lt) 2022-03-25
ME00238B (me) 2011-02-10
SK287737B6 (sk) 2011-08-04

Similar Documents

Publication Publication Date Title
AR020934A1 (es) Compuestos trombopoyeticos
BR0116831A (pt) Composição oral e seu uso
BR8900950A (pt) Composicao dentifricia listrada estavel
MX167330B (es) Composiciones microbiocidas estabilizadas con fenol
ES2173284T3 (es) Agentes endoparasicitidas.
FI863797A7 (fi) N-terminaaliselle metioniinille spesifinen peptidaasi, sen tuottaminen ja käyttö.
FR2654932B1 (fr) Composition anorexigene.
FI904444A0 (fi) Aktiva limkompositioner.
FI904801A0 (fi) Komposition.
DE58904645D1 (de) Tensidkombination.
DE68923863D1 (de) Ein-/Ausgabecachespeicherung.
DE68908500D1 (de) Dentalzusammensetzung.
DE69012702D1 (de) Dentalzusammensetzung.
DE68921181D1 (de) Bleichmittelzusammensetzung.
DE69034070D1 (de) Racemisches Huperzin A
AR244544A1 (es) Composicion desodorante.
IT8920068A0 (it) Composizione deodorante.
DE60109179D1 (de) Quantenkaskadierter laser
DE69023059D1 (de) Verschmutzungsverhindernde Zusammensetzung.
AR244941A1 (es) Compuesto, composicion, procedimiento y uso antimicrobiano.
FI900862A0 (fi) Hoegeffektiva polarisatorer.
ATE359768T1 (de) Pflaster
ES2044100T3 (es) Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.
DE68919488D1 (de) Antimikrobielle Zusammensetzung.
DE68919500D1 (de) Bleichmittelzusammensetzung.

Legal Events

Date Code Title Description
FG Grant, registration